1. Home
  2. IPSC vs TBI Comparison

IPSC vs TBI Comparison

Compare IPSC & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

HOLD

Current Price

$1.44

Market Cap

268.0M

Sector

Health Care

ML Signal

HOLD

Logo TrueBlue Inc.

TBI

TrueBlue Inc.

SELL

Current Price

$8.81

Market Cap

311.4M

ML Signal

SELL

Company Overview

Basic Information
Metric
IPSC
TBI
Founded
2019
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
268.0M
311.4M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
IPSC
TBI
Price
$1.44
$8.81
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$4.75
★ $9.75
AVG Volume (30 Days)
★ 690.4K
229.0K
Earning Date
11-12-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 91.30
61.39
EPS
★ N/A
N/A
Revenue
★ $109,164,000.00
N/A
Revenue This Year
N/A
$8.10
Revenue Next Year
N/A
$3.33
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 1556.76
N/A
52 Week Low
$0.44
$3.18
52 Week High
$2.97
$11.03

Technical Indicators

Market Signals
Indicator
IPSC
TBI
Relative Strength Index (RSI) 34.68 41.59
Support Level $0.90 $8.63
Resistance Level $2.62 $8.90
Average True Range (ATR) 0.12 0.35
MACD -0.02 -0.05
Stochastic Oscillator 31.43 8.51

Price Performance

Historical Comparison
IPSC
TBI

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.

Share on Social Networks: